Natera Gains Japan Approval for Signatera Cancer Test
1h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
naterasignateracancer-test
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Natera, Inc. announced on June 24, 2026, that it has received regulatory approval from Japan’s Ministry of Health, Labour and Welfare for its Signatera molecular residual disease test. The clearance authorizes the use of Signatera for detecting circulating tumor DNA in the blood of colorectal cancer patients after surgery, a critical step for a company targeting global oncology markets. The Japanese approval follows similar regulatory successes in the United States and Europe, positioning Natera for entry into Asia’s second-largest healthcare economy. The decision immediately expands the total addressable market for Signatera by a population of over 125 million people.
Japan’s pharmaceutical and medical device regulator operates a rigorous, multi-year review process, making this approval a significant validation for the clinical utility of Signatera’s technology. The last major international regulatory win for a U.S.-based liquid biopsy company was Guardant Health receiving FDA approval for its Shield colorectal cancer screening test in August 2024. Natera’s approval arrives amidst a global push to integrate molecular diagnostics into standard cancer care pathways, particularly for monitoring recurrence.
The current macro backdrop features elevated interest rates, pressuring high-growth, cash-burning life science companies to demonstrate clear paths to profitability. Natera’s core business has been driven by its prenatal testing segment, but oncology represents its primary growth vector. The catalyst for the approval now is likely the accumulation of strong clinical validation data, including results from the CIRCULATE-Japan study which demonstrated Signatera’s predictive power for recurrence in colorectal cancer patients.
Japan’s aging demographic profile creates a high-incidence environment for cancers like colorectal cancer, which has over 160,000 new cases annually in the country. The approval allows Natera to begin commercial reimbursement negotiations with Japan’s national health insurance system, a process that typically concludes within 12-18 months. Securing favorable reimbursement rates is the critical next step for translating regulatory success into meaningful revenue.
The Japanese in vitro diagnostics market was valued at approximately $8.7 billion in 2025, with oncology diagnostics representing a rapidly growing segment. Natera reported total revenue of $1.21 billion for the full year 2025, with oncology revenue contributing roughly $350 million. The company’s oncology test volume grew 42% year-over-year in Q1 2026, reaching over 65,000 tests. Signatera’s list price in the U.S. is around $3,500 per test, though realized prices are lower due to payer contracts.
For a peer comparison, Guardant Health reported 2025 revenue of $741 million, with its screening and surveillance units seeing rapid growth. Illumina, a provider of sequencing tools used by Natera and its rivals, reported $4.54 billion in 2025 revenue. The market capitalization of Natera immediately following the announcement was approximately $9.8 billion, compared to Guardant Health’s $11.2 billion. The table below shows the revenue mix shift for Natera from 2023 to 2025.
| Segment | 2023 Revenue | 2025 Revenue |
|---|---|---|
| Women's Health | $720M | $860M |
| Oncology | $180M | $350M |
Natera’s operating loss narrowed to $245 million in 2025 from $435 million in 2023, indicating progress toward its goal of reaching adjusted EBITDA breakeven by late 2027. The company ended Q1 2026 with $825 million in cash, cash equivalents, and short-term investments. The gross margin for its oncology segment improved to 58% in 2025, up from 51% two years prior.
The approval is a direct positive for Natera (NTRA), providing a new, sizable revenue stream that could accelerate its path to profitability. It strengthens Natera’s competitive position against Guardant Health (GH) and Exact Sciences (EXAS) in the global liquid biopsy race. Diagnostic equipment suppliers like Illumina (ILMN) and Thermo Fisher Scientific (TMO) stand to benefit from increased consumables demand as test volumes grow. Japanese pharmaceutical distributors and lab service providers, such as SRL, Inc., may see new partnership opportunities.
A key limitation is the pending reimbursement negotiation. Japan’s health system is known for driving hard bargains, which could pressure the test’s average selling price below U.S. levels. local competitors like Sysmex and LSIP Medience are developing their own MRD assays, ensuring the market will not be uncontested. The approval does not immediately change Natera’s near-term cash burn, requiring continued capital market access.
Positioning data from options markets and institutional 13F filings showed increased bullish call buying on NTRA in the weeks leading to the decision, suggesting some anticipation. Flow has likely rotated from pure-play U.S. diagnostic names toward companies with clearer international regulatory catalysts. Short interest in NTRA remained elevated at around 12% of float prior to the announcement, indicating a significant cohort of investors skeptical of its valuation and cash burn profile.
The primary catalyst is Japan’s reimbursement decision, expected by Q2 2027. Natera’s Q2 2026 earnings call, scheduled for August 5, 2026, will provide initial commentary on launch strategy and partnership plans in Japan. Investors should monitor the company’s guidance for 2026 oncology revenue, which may be revised upward to reflect the new market opportunity.
Key levels to watch include NTRA’s stock price holding above its 200-day moving average, currently near $78.50, as a sign of sustained bullish momentum. A failure to secure a reimbursement price above $2,000 per test in Japan would be viewed negatively. The next major regulatory milestone is potential FDA approval for Signatera in earlier-stage cancer indications, with a Prescription Drug User Fee Act date anticipated in H1 2027.
Competitive response is another watch point. Guardant Health may accelerate submissions for its LUNAR assay in Asian markets. Exact Sciences’ Cologuard, a stool-based screening test, could face renewed competitive pressure in colorectal cancer surveillance if Signatera gains rapid adoption. Updates from the CIRCULATE-Japan study’s overall survival data, expected in late 2026, will be critical for reinforcing clinical utility to Japanese oncologists.
For retail investors, the approval reduces a key regulatory risk and validates Natera's global expansion thesis, potentially making the stock less volatile to U.S.-centric news. It does not immediately change the company's financials, as revenue will ramp slowly following reimbursement. Investors should focus on the company's quarterly cash burn and oncology test volume growth, as profitability remains several quarters away. The development may lead to increased analyst coverage and institutional ownership.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.